A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
Fujimoto T, Abe Y, Igarashi M, Ishikoh A, Omi T, Kanda H, Kitahara H, Kinoshita M, Nakasu I, Hattori N, Horiuchi Y, Maruyama R, Mizutani H, Murakami Y, Watanabe C, Kume A, Hanafusa T, Hamaguchi M, Yoshioka A, Egami Y, Matsuo K, Matsuda T, Akamatsu M, Yorozuya T, Takayama S, Yokozeki H.
Fujimoto T, et al. Among authors: abe y.
J Dermatol. 2021 Aug;48(8):1149-1161. doi: 10.1111/1346-8138.15927. Epub 2021 May 26.
J Dermatol. 2021.
PMID: 34041788
Free PMC article.
Clinical Trial.